Acadian Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-34,691
| Closed | -$2.74M | – | 2132 |
|
|
2025
Q4 | $2.74M | Sell |
34,691
-75,753
| -69% | -$5.7M | ﹤0.01% | 835 |
|
|
2025
Q3 | $7.21M | Buy |
+110,444
| New | +$5.39M | 0.01% | 551 |
|
|
2024
Q4 | – | Sell |
-6,328
| Closed | -$253K | – | 1885 |
|
|
2024
Q3 | $253K | Buy |
+6,328
| New | +$294K | ﹤0.01% | 1284 |
|
|
2024
Q2 | – | Sell |
-5,891
| Closed | -$255K | – | 1829 |
|
|
2024
Q1 | $255K | Buy |
+5,891
| New | +$281K | ﹤0.01% | 1146 |
|
|
2023
Q2 | – | Sell |
-3,073
| Closed | -$109K | – | 1820 |
|
|
2023
Q1 | $109K | Buy |
+3,073
| New | +$115K | ﹤0.01% | 1379 |
|
|
2022
Q4 | – | Sell |
-20,390
| Closed | -$898K | – | 1845 |
|
|
2022
Q3 | $898K | Buy |
+20,390
| New | +$859K | ﹤0.01% | 836 |
|
|
2021
Q2 | – | Sell |
-2,378
| Closed | -$107K | – | 2099 |
|
|
2021
Q1 | $107K | Sell |
2,378
-32,026
| -93% | -$1.79M | ﹤0.01% | 1659 |
|
|
2020
Q4 | $1.95M | Buy |
34,404
+9,247
| +37% | +$461K | 0.01% | 764 |
|
|
2020
Q3 | $1.19M | Sell |
25,157
-33,366
| -57% | -$1.85M | 0.01% | 843 |
|
|
2020
Q2 | $3.45M | Buy |
58,523
+57,420
| +5,206% | +$3.19M | 0.01% | 569 |
|
|
2020
Q1 | $52K | Sell |
1,103
-1,907
| -63% | -$106K | ﹤0.01% | 1495 |
|
|
2019
Q4 | $182K | Buy |
+3,010
| New | +$179K | ﹤0.01% | 1315 |
|
|
2019
Q3 | – | Sell |
-963
| Closed | -$62K | – | 1936 |
|
|
2019
Q2 | $62K | Buy |
963
+24
| +3% | +$1.7K | ﹤0.01% | 1441 |
|
|
2019
Q1 | $76K | Sell |
939
-2,889
| -75% | -$186K | ﹤0.01% | 1584 |
|
|
2018
Q4 | $207K | Buy |
3,828
+3,670
| +2,323% | +$187K | ﹤0.01% | 1111 |
|
|
2018
Q3 | $8K | Hold |
158
| – | – | ﹤0.01% | 1569 |
|
|
2018
Q2 | $7K | Buy |
158
+110
| +229% | +$4.88K | ﹤0.01% | 1611 |
|
|
2018
Q1 | $2K | Sell |
48
-2,781
| -98% | -$141K | ﹤0.01% | 1645 |
|
|
2017
Q4 | $143K | Sell |
2,829
-551
| -16% | -$30.2K | ﹤0.01% | 1020 |
|
|
2017
Q3 | $171K | Buy |
+3,380
| New | +$177K | ﹤0.01% | 942 |
|
|
2017
Q2 | – | Sell |
-143
| Closed | -$6K | – | 1507 |
|
|
2017
Q1 | $6K | Buy |
+143
| New | +$6.42K | ﹤0.01% | 1460 |
|
|
2016
Q1 | – | Sell |
-134
| Closed | -$8K | – | 1415 |
|
|
2015
Q4 | $8K | Sell |
134
-76
| -36% | -$4.1K | ﹤0.01% | 1264 |
|
|
2015
Q3 | $9K | Buy |
+210
| New | +$10.9K | ﹤0.01% | 1146 |
|
Other funds holding IONS
VPM
VCM
Acadian Asset Management's IONS Position: Q1 2026 in Review
Acadian Asset Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2026, closing a stake of 34,691 shares — an estimated $2.74M sold.
Acadian Asset Management first reported a position in IONS in Q3 2015 and held it in 23 quarters. The position peaked at $7.21M in Q3 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Acadian Asset Management reported no remaining Ionis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Acadian Asset Management sold 34,691 Ionis Pharmaceuticals shares in Q1 2026, an estimated $2.74M.
- Acadian Asset Management first reported a position in Ionis Pharmaceuticals in Q3 2015 and held it in 23 quarters.
- Acadian Asset Management's Ionis Pharmaceuticals position peaked at $7.21M in Q3 2025.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.